WO2011066201A3 - Methods and systems for treating and preventing cardiac injury in dystrophic subjects - Google Patents

Methods and systems for treating and preventing cardiac injury in dystrophic subjects Download PDF

Info

Publication number
WO2011066201A3
WO2011066201A3 PCT/US2010/057560 US2010057560W WO2011066201A3 WO 2011066201 A3 WO2011066201 A3 WO 2011066201A3 US 2010057560 W US2010057560 W US 2010057560W WO 2011066201 A3 WO2011066201 A3 WO 2011066201A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating
systems
methods
cardiac injury
preventing cardiac
Prior art date
Application number
PCT/US2010/057560
Other languages
French (fr)
Other versions
WO2011066201A2 (en
Inventor
Joseph M. Metzger
Dewayne Townsend
Original Assignee
The Regents Of The University Of Michigan
Regents Of The University Of Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of Michigan, Regents Of The University Of Minnesota filed Critical The Regents Of The University Of Michigan
Publication of WO2011066201A2 publication Critical patent/WO2011066201A2/en
Publication of WO2011066201A3 publication Critical patent/WO2011066201A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Abstract

The present invention provides methods for treating and preventing cardiac deficiencies and injuries (e.g., cardiac injury and ventricular dilation) in dystrophic subjects using poloxamer containing compositions. In some embodiments, the polaxamers are administered to dystrophic subjects prior to cardiac stress, such as that caused by anaesthesia. In other embodiments, the present invention provides systems comprising poloxamer compositions and at least one anaesthetic agent.
PCT/US2010/057560 2009-11-25 2010-11-22 Methods and systems for treating and preventing cardiac injury in dystrophic subjects WO2011066201A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26456009P 2009-11-25 2009-11-25
US61/264,560 2009-11-25

Publications (2)

Publication Number Publication Date
WO2011066201A2 WO2011066201A2 (en) 2011-06-03
WO2011066201A3 true WO2011066201A3 (en) 2011-11-10

Family

ID=44067186

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/057560 WO2011066201A2 (en) 2009-11-25 2010-11-22 Methods and systems for treating and preventing cardiac injury in dystrophic subjects

Country Status (1)

Country Link
WO (1) WO2011066201A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102218077A (en) 2006-08-01 2011-10-19 普里克萨斯医药股份有限公司 Use of poloxamer for the prevention and/or treatment of heart failure
US8852568B2 (en) 2007-12-17 2014-10-07 The Regents Of The University Of Michigan Compositions and methods for treating and preventing skeletal muscle deficiencies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US20030124190A1 (en) * 2000-06-26 2003-07-03 Epicept, Inc. Methods and compositions for treating pain of the mucous membrane
US20040253277A1 (en) * 2001-08-24 2004-12-16 John Meadows Anaesthetic formulations of propofol
US20040265388A1 (en) * 2002-07-29 2004-12-30 Zhong Zhang Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US20030124190A1 (en) * 2000-06-26 2003-07-03 Epicept, Inc. Methods and compositions for treating pain of the mucous membrane
US20040253277A1 (en) * 2001-08-24 2004-12-16 John Meadows Anaesthetic formulations of propofol
US20040265388A1 (en) * 2002-07-29 2004-12-30 Zhong Zhang Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses

Also Published As

Publication number Publication date
WO2011066201A2 (en) 2011-06-03

Similar Documents

Publication Publication Date Title
NO20100301L (en) Improved brimonidine compositions for the treatment of erythema
EP3682875A3 (en) Methods of treating pediatric metabolic syndrome
DOP2006000057A (en) PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
WO2008089268A3 (en) Methods and compositions for treating conditions associated with infection and/or inflammation
WO2009109618A3 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1
AR090491A1 (en) TREATMENT OF MULTIPLE SCLEROSIS WITH A COMBINATION OF LAQUINIMOD AND DIMETILO FUMARATE
WO2011044506A3 (en) Sulphone compounds for use in the treatment of obesity
WO2009109616A8 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
BR112014031394A2 (en) compositions and methods for transmucosal absorption
WO2014081702A3 (en) Synthetic linear apelin mimetics for the treatment of heart failure
MX2012000275A (en) Acid pump antagonist for treatment of diseases associated with abnormal gastrointestinal movement.
PH12014502448A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
PH12014501937A1 (en) Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative
MX2010009624A (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1.
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
BR112015011778A2 (en) methods for administering and evaluating nitrogen expulsion drugs for the treatment of hepatic encephalopathy
BR112012019921A2 (en) liquid compositions comprising a non-metol cooling agent and a thickener for treating a respiratory symptom.
WO2010090494A3 (en) Medical use of 5-benzylaminosalicylic acid derivatives or salts thereof
PE20150345A1 (en) NEW COMPOUND THAT HAS THE CAPACITY TO INHIBIT THE ENZYME DEHYDROGENASE 11B-HYDROXIESTEROID TYPE 1 (11B-HSD1) OR PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME, A METHOD TO PRODUCE THE SAME, AND A COMPOSITION AS A PHARMACEUTICALLY INHIBITED PHARMACEUTICAL ACTIVE INN
WO2009019708A3 (en) Pharmaceutical compositions and methods for the treatment of cancer
BR112012022209A2 (en) pharmaceutical compositions comprising monoterpenes
WO2011066201A3 (en) Methods and systems for treating and preventing cardiac injury in dystrophic subjects
NZ754706A (en) Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus
WO2010151004A3 (en) Injectable composition containing hydroxychloroquine for local administration for treating hemorrhoids

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10833808

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10833808

Country of ref document: EP

Kind code of ref document: A2